Latest Breaking News On - Karsten fischer - Page 3 : comparemela.com

Memo Therapeutics AG Announces Positive Phase I Data with AntiBKV for Treatment of BKV Infection in Renal Transplant Patients

Memo Therapeutics AG Announces Positive Phase I Data with AntiBKV for Treatment of BKV Infection in Renal Transplant Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Mike sinclairKarsten fischerAccelagen pty ltdWall streetInvestigational new drug applicationChief medical officerMemo therapeuticsChief executive officerVakzine project management gmbh

Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets

Memo Therapeutics AG ("MTx"), an innovator in the field of antibody discovery and development, announced today the signing of a research and development collaboration agreement with Ono Pharmaceutical

Toichi takinoChristoph esslingerMike sinclairKarsten fischerOno pharmaceutical coDiscovery research of onoLtd onoMemo therapeuticsOno pharmaceuticalChief scientific officerSenior executive officer directorDiscovery research

Memo Therapeutics Raises CHF23M Extension; Closes CHF37M Series B Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Karsten fischerPgf groupMemo therapeuticsSwisscanto investAdjuvant capitalFresenius medical care venturesVerve venturesVesalius biocapitalChief executive officerBio technopark zurich

Memo Therapeutics AG to clinically develop SARS-CoV-2 antibody

Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.

Christoph esslingerKarsten fischerSwiss federal funding programmeSwiss governmentZurich headquartered memo therapeuticsChief scientific officerMemo therapeuticsBio developmentsMonoclonal antibodiesCovid 19

Memo Therapeutics AG to clinically develop SARS-CoV-2 antibody

Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.

Christoph esslingerKarsten fischerSwiss federal funding programmeSwiss governmentZurich headquartered memo therapeuticsChief scientific officerMemo therapeuticsDrug deliveryClinical developmentCovid 19Linical evolutionDelivery formulationsDelivery technologiesHasei iiMonoclonal antibodies